Navigation Links
CET Life Sciences Center Welcomes Belmont University School of Pharmacy as New Tenant
Date:7/1/2008

Lab to promote collaborative ventures between Belmont's School of Pharmacy

and health care providers

NASHVILLE, Tenn., July 1 /PRNewswire/ -- Cumberland Emerging Technologies, Inc. (CET) today announced that Belmont University has established the Belmont School of Pharmacy Department of Pharmaceutical Sciences Laboratory at the CET Life Sciences Center. The Life Sciences Center, which is located in downtown Nashville, provides lab and office space, equipment and infrastructure to early-stage biopharmaceutical ventures.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080701/CLTU108 )

Belmont has leased the space to support research and service programs of its School of Pharmacy. The primary objective of the lab is to provide dosage form development, characterization and quality analysis. The school will work with the pharmaceutical industry and local and regional health care providers to meet previously unmet and emerging needs related to drug delivery.

The work being performed at the Life Sciences Center is designed to help provide drug delivery solutions, which is unique to pharmacy practice and which, until now, has not played a major role in middle Tennessee's robust health care scene," said Dr. Andrew Webster, Chair and Professor of Pharmaceutical Sciences at Belmont's School of Pharmacy. "By partnering with CET, our faculty and students have access to a community of resources to advance research that will help drug developers bring their products to patients who need them most."

"We are delighted to welcome Belmont School of Pharmacy to our growing roster of tenants at the Life Sciences Center," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals and CET. "Partnering with outstanding academic research and training programs like this one is a key component of CET's strategy, and we look forward to providing laboratory and equipment infrastructure to support their promising research."

Belmont's School of Pharmacy announced last week that it has received approval from The Accreditation Council for Pharmacy Education (ACPE) to seat its first class of 75 students for the 2008-09 academic year.

Belmont University, host of the 2008 Town Hall Presidential Debate, is a fast-growing community of nearly 4,800 students who come from almost every state and more than 25 countries. Committed to being a leader among teaching universities, Belmont brings together the best of liberal arts and professional education in a Christian community of learning and service. Belmont's purpose is to help students explore their passions and develop their talents to meet the world's needs. With more than 75 areas of study, 12 master's programs and three doctoral degrees, there is no limit to the ways Belmont University can expand an individual's horizon. For more information, visit http://www.belmont.edu.

Cumberland Emerging Technologies, Inc. (http://www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.


'/>"/>
SOURCE Cumberland Emerging Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... 2017 According to a ... (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication ... and Development, Disease-Risk) - Global Forecast to 2021" ... reach USD 53.34 Billion by 2021 from USD ... of 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... 2017  If only one in every hundred ... resistance to chemotherapy, thousands of cancer cells would ... on finding these mutations in ever-smaller subpopulations of ... DNA in blood — to guide treatment decisions ... Unfortunately, however, detecting these genetic anomalies may be ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... will present at the LEERINK Partners 6th Annual Global ... on Wednesday, February 15, 2017 at 10 a.m. Eastern ... presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  The ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:2/6/2017)... , Feb. 6, 2017 According ... security are driving border authorities to continue to ... reports there are 2143 Automated Border Control (ABC) ... currently deployed at more than 163 ports of ... 2013 to 2016 achieving a combined CAGR of ...
Breaking Biology News(10 mins):